Phosphorus ( DrugBank: Phosphorus )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	2
238	Vitamin D-resistant rickets	2

8. Huntington disease

---

Clinical trials : 229 /  Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01882062 (ClinicalTrials.gov)	May 2013	18/6/2013	Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease		Huntington Disease	Drug: Triheptanoin 1g/kg/day	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Completed	18 Years	N/A	All	10	Phase 2	France
2	NCT01696708 (ClinicalTrials.gov)	December 6, 2012	20/9/2012	Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease	Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease	Huntington Disease	Other: 31-Phosphorus RMN Spectroscopy	Institut National de la Santé Et de la Recherche Médicale, France	NULL	Completed	18 Years	N/A	All	50	N/A	France

238. Vitamin D-resistant rickets

---

Clinical trials : 29 /  Drugs : 25 - (DrugBank : 11) / Drug target genes : 4 - Drug target pathways : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-101332	01/9/2010	02/11/2010	Therapeutic use of Z-521	Therapeutic use of oral sodium phosphate (Z-521) in primary hypophosphatemic rickets (familial rickets, X-linked hypophosphatemia, vitamin D-resistant rickets)	primary hypophosphatemic rickets	Intervention name : Z-521 Dosage And administration of the intervention : 300-3000mg inorganic phosphorus is orally administered in 3 or 4 times per day	Zeria Pharmaceutical Co., Ltd.	NULL		1	14	BOTH	10	Phase 3	NULL
2	ChiCTR-OOC-16010095	2006-01-01	2016-12-07	Oral Phosphate Supplements Play an Important Role in Improving the Bone Mineral Density of Hypophosphatemic Osteomalacia Patients	Effect of Phosphate on hypophosphatemia	Hypophosphatemic Osteomalacia	A1:received phosphate solution doses at a frequency dependent upon measured serum phosphorus levels;A2:received phosphate solution doses only every three to four days;A3:received no phosphate solution;A:Hypophosphatemic Osteomalacia;B:Control;	The Second Xiangya Hospital, Central South University	NULL	Completed			Both	A1:3;A2:5;A3:3;A:21;B:105;		China